2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy

@article{Herrstedt20162016UM,
  title={2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy},
  author={J{\o}rn Herrstedt and Fausto Roila and David Warr and Luigi Celio and Rudolph M. Navari and Paul J. Hesketh and Alexandre Chan and Matti Aapro},
  journal={Supportive Care in Cancer},
  year={2016},
  volume={25},
  pages={277-288}
}
PurposeThis review summarizes the recommendations for the prophylaxis of nausea and vomiting in adults receiving highly emetogenic chemotherapy (HEC) which includes cisplatin, mechlorethamine, streptozocin, cyclophosphamide >1500 mg/m2, carmustine, dacarbazine, and the combination of an anthracycline and cyclophosphamide (AC) administered to women with breast cancer, as agreed at the MASCC/ESMO Antiemetic Guidelines Update meeting in Copenhagen in June 2015.MethodsA systematic review of the… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 26 CITATIONS

Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists

VIEW 22 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Alterations of colonic sensitivity and gastric dysmotility after acute cisplatin and granisetron.

  • Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 45 REFERENCES

Drug–drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data

  • Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • 2016
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe.

  • Clinical pharmacology and therapeutics
  • 2003
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

Antiemetic therapy for multiple-day chemotherapy, high dose che- motherapy, and breakthrough nausea and vomiting: review and consensus statements

LH Einhorn, B Rapoport, R Navari, J Herrstedt
  • BramesMJ
  • 2016
VIEW 1 EXCERPT